5 research outputs found
Representative chromatograms.
<p>A) Blank human plasma, B) Efavirenz in human plasma at Lowest limit of quantification (LLOQ, 1.0 ng/mL) and C) <sup>13</sup>C<sub>6</sub>-Efavirenz (Internal standard, 10 ng/mL) in human plasma.</p
HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions.
<p>Accuracy and precision for Efavirenz Calibration standards in human plasma.</p
Summary of Validation outcomes of Efavirenz in human plasma.
<p>Summary of Validation outcomes of Efavirenz in human plasma.</p
Summary of stability outcomes of Efavirenz in human plasma.
<p>Summary of stability outcomes of Efavirenz in human plasma.</p
Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B‑Raf-Driven Tumors
Hyperactive signaling of the MAP
kinase pathway resulting from
the constitutively active B-Raf<sup>V600E</sup> mutated enzyme has
been observed in a number of human tumors, including melanomas. Herein
we report the discovery and biological evaluation of GSK2118436, a
selective inhibitor of Raf kinases with potent in vitro activity in
oncogenic B-Raf-driven melanoma and colorectal carcinoma cells and
robust in vivo antitumor and pharmacodynamic activity in mouse models
of B-Raf<sup>V600E</sup> human melanoma. GSK2118436 was identified
as a development candidate, and early clinical results have shown
significant activity in patients with B-Raf mutant melanoma